Current and historical daily PE Ratio for China National Accord Medicines Corp Ltd (
) from 1993 to May 29 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. China National Accord Medicines stock (SZSE:000028) PE ratio as of May 29 2023 is 15.92.
More Details
China National Accord Medicines Corp Ltd (SZSE:000028) PE Ratio (TTM) Chart
China National Accord Medicines Corp Ltd (SZSE:000028) PE Ratio (TTM) Historical Data
View and export this data going back to 1993. Start your Free Trial
Total 1194
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| China National Accord Medicines PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-05-29 | 16.1 | 2023-03-21 | 13.2 |
| 2023-05-26 | 15.8 | 2023-03-20 | 13.4 |
| 2023-05-25 | 15.1 | 2023-03-17 | 14.1 |
| 2023-05-24 | 15.2 | 2023-03-16 | 13.4 |
| 2023-05-23 | 15.2 | 2023-03-15 | 12.2 |
| 2023-05-22 | 15.8 | 2023-03-14 | 12.1 |
| 2023-05-19 | 16.1 | 2023-03-13 | 12.0 |
| 2023-05-18 | 16.0 | 2023-03-10 | 11.9 |
| 2023-05-17 | 15.6 | 2023-03-09 | 12.4 |
| 2023-05-16 | 15.2 | 2023-03-08 | 12.5 |
| 2023-05-15 | 15.2 | 2023-03-07 | 11.9 |
| 2023-05-12 | 15.0 | 2023-03-06 | 11.6 |
| 2023-05-11 | 14.9 | 2023-03-03 | 11.1 |
| 2023-05-10 | 15.7 | 2023-03-02 | 10.9 |
| 2023-05-09 | 15.7 | 2023-03-01 | 10.9 |
| 2023-05-08 | 16.3 | 2023-02-28 | 10.9 |
| 2023-05-05 | 16.5 | 2023-02-27 | 10.6 |
| 2023-05-04 | 17.2 | 2023-02-24 | 10.7 |
| 2023-04-28 | 17.4 | 2023-02-23 | 10.7 |
| 2023-04-27 | 17.4 | 2023-02-22 | 10.7 |
| 2023-04-26 | 15.9 | 2023-02-21 | 10.7 |
| 2023-04-25 | 16.1 | 2023-02-20 | 10.6 |
| 2023-04-24 | 15.5 | 2023-02-17 | 10.6 |
| 2023-04-21 | 14.5 | 2023-02-16 | 10.5 |
| 2023-04-20 | 15.2 | 2023-02-15 | 10.3 |
| 2023-04-19 | 14.5 | 2023-02-14 | 10.2 |
| 2023-04-18 | 14.3 | 2023-02-13 | 9.9 |
| 2023-04-17 | 14.7 | 2023-02-10 | 9.8 |
| 2023-04-14 | 13.4 | 2023-02-09 | 9.9 |
| 2023-04-13 | 13.3 | 2023-02-08 | 9.8 |
| 2023-04-12 | 12.8 | 2023-02-07 | 10.0 |
| 2023-04-11 | 13.1 | 2023-02-06 | 9.9 |
| 2023-04-10 | 12.5 | 2023-02-03 | 10.0 |
| 2023-04-07 | 12.5 | 2023-02-02 | 10.2 |
| 2023-04-06 | 12.5 | 2023-02-01 | 10.1 |
| 2023-04-04 | 12.6 | 2023-01-31 | 10.1 |
| 2023-04-03 | 11.9 | 2023-01-30 | 10.1 |
| 2023-03-31 | 11.8 | 2023-01-20 | 10.3 |
| 2023-03-30 | 11.7 | 2023-01-19 | 10.3 |
| 2023-03-29 | 11.9 | 2023-01-18 | 10.1 |
| 2023-03-28 | 11.9 | 2023-01-17 | 10.1 |
| 2023-03-27 | 12.6 | 2023-01-16 | 10.1 |
| 2023-03-24 | 12.8 | 2023-01-13 | 10.2 |
| 2023-03-23 | 13.1 | 2023-01-12 | 10.2 |
| 2023-03-22 | 13.1 | 2023-01-11 | 10.1 |
China National Accord Medicines Corp Ltd (SZSE:000028) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
China National Accord Medicines Corp Ltd
NAICS : 325411
ISIN : CNE0000009N6
Compare
Compare
Traded in other countries / regions
000028.China IPO Date
1993-08-09Description
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
